Author: Zhiheng Xu; Jianmeng Zhou; Yongbo Huang; Xuesong Liu; Yonghao Xu; Sibei Chen; Dongdong Liu; Zhimin Lin; Xiaoqing Liu; Yimin Li
Title: The efficacy of convalescent plasma for the treatment of severe influenza Document date: 2020_2_23
ID: 4pe9o59g_49
Snippet: According to the findings of high quality RCTs, we did not identify passive immunotherapy as an adjunctive therapy providing clinical benefit for patients with severe influenza. Therefore, for patients with COVID-19, clinicians should take such previous findings carefully into considerations before the use of convalescent plasma in critically ill SARS-CoV-2 infected patients. The composition of the plasma is complex. And the antibodies produced b.....
Document: According to the findings of high quality RCTs, we did not identify passive immunotherapy as an adjunctive therapy providing clinical benefit for patients with severe influenza. Therefore, for patients with COVID-19, clinicians should take such previous findings carefully into considerations before the use of convalescent plasma in critically ill SARS-CoV-2 infected patients. The composition of the plasma is complex. And the antibodies produced by the human body are matched with its own immune system. Transfusion reactions may occur in blood products administration (20, 21) . In addition, the titers of the antibody from convalescent may differ from each other. The standardized extraction and purification specific antibody may be a difficult and time consuming work, which might not suitable for the current outbreak of SARS-CoV-2. Finally, pilot study and control trials should be carried out to identify the optimal timing, dosage and indications in the use of H-IVIG/immune plasma in patients with COVID-19.
Search related documents:
Co phrase search for related documents- adjunctive therapy and clinical benefit: 1, 2, 3, 4
- adjunctive therapy and control study: 1, 2
- adjunctive therapy and convalescent plasma: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- antibody titer and blood product: 1, 2
- antibody titer and clinical benefit: 1, 2
- antibody titer and control study: 1, 2, 3, 4, 5, 6
- antibody titer and convalescent antibody titer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- antibody titer and convalescent plasma: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- blood product and convalescent antibody titer: 1
- blood product and convalescent plasma: 1, 2, 3, 4, 5, 6, 7, 8
- blood product and current outbreak: 1
- clinical benefit and control study: 1, 2, 3, 4, 5, 6, 7, 8
- clinical benefit and convalescent antibody titer: 1
- clinical benefit and convalescent plasma: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical benefit and current outbreak: 1, 2
- control study and convalescent antibody titer: 1
- control study and convalescent plasma: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- control study and current outbreak: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- convalescent plasma and high quality rct: 1
Co phrase search for related documents, hyperlinks ordered by date